We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

27 hedge funds and large institutions have $8.88M invested in Moleculin Biotech in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

336% more capital invested

Capital invested by funds: $2.04M → $8.88M (+$6.84M)

45% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 11

23% more funds holding

Funds holding: 22 → 27 (+5)

0.02% more ownership

Funds ownership: 0% → 0.02% (+0.02%)

Holders
27
Holders Change
+5
Holders Change %
+22.73%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
5
Reduced
–
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Sio Capital Management
New York
+$4.71M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.81M
3
BlackRock
BlackRock
New York
+$1.13M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$614K
5
Northern Trust
Northern Trust
Illinois
+$174K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$756K
2
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$105K
3
UBS Group
UBS Group
Switzerland
-$29K
4
HighTower Advisors
HighTower Advisors
Illinois
-$21K
5
LWMG
Levy Wealth Management Group
Pennsylvania
-$11K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$1K – – –
Carson Wealth (CWM LLC)
27
Carson Wealth (CWM LLC)
Nebraska
$1K +$1.83K +1 New
GRP
28
Global Retirement Partners
California
$1K +$1.83K +1 New
NSIM
29
North Star Investment Management
Illinois
$1K +$1.83K +1 New
Renaissance Technologies
30
Renaissance Technologies
New York
– -$756K -422 Closed
Qube Research & Technologies (QRT)
31
Qube Research & Technologies (QRT)
United Kingdom
– -$105K -59 Closed
UBS Group
32
UBS Group
Switzerland
– -$29K -16 Closed
HighTower Advisors
33
HighTower Advisors
Illinois
– -$21K -12 Closed
LWMG
34
Levy Wealth Management Group
Pennsylvania
– -$11K -6 Closed
HF
35
HRT Financial
New York
– -$8K -5 Closed
WIC
36
Woodmont Investment Counsel
Tennessee
– -$10K -5 Closed
TRCT
37
Tower Research Capital (TRC)
New York
– -$7K -4 Closed
Barclays
38
Barclays
United Kingdom
– -$5K -3 Closed
CWAF
39
Core Wealth Advisors (Florida)
Florida
– -$1K -1 Closed
TPWA
40
TRUE Private Wealth Advisors
Oregon
– -$1K -1 Closed
1
2

MBRX Hedge Fund Activity: Q1 2021 in Review

27 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2021, worth a combined $8.88M — up 336% from $2.04M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new MBRX positions and 11 closed out — a net gain of 5 holders — while 5 added to existing stakes and 0 trimmed.

The largest buyer was Sio Capital Management, opening a new position worth an estimated $4.71M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $756K sold.

  • 27 institutional investors held Moleculin Biotech (MBRX) as of Q1 2021, up from 22 in Q4 2020.
  • Funds reported $8.88M of Moleculin Biotech stock for Q1 2021, up 336% quarter-over-quarter.
  • 16 funds opened new Moleculin Biotech positions in Q1 2021 and 11 closed out, a net change of +5 holders.
  • The largest Moleculin Biotech buyer in Q1 2021 was Sio Capital Management, an estimated $4.71M added.
  • The largest Moleculin Biotech seller in Q1 2021 was Renaissance Technologies, an estimated $756K sold.

Based on aggregated 13F filings for Q1 2021.